Can Novo Nordisk (NYSE:NVO) Trade Below Fair Value On Earnings?

What happened: Novo Nordisk shares trade at US$40.00, and the article examines whether that level is supported by earnings given new obesity and diabetes treatments and tougher competition. Key numbers: Share price US$40.00, down 56.7% over 3 years. P/E 10.1x versus Pharmaceuticals sector average 16.0x and peer group 61.3x. Why it matters: The article says the 10.1x multiple screens as undervalued on its framework, and that Citi has flagged tougher GLP-1 competition from Eli Lilly, suggesting the market already prices in a fair amount of that pressure. Market: +2.2% today ($40.00), -20.8% YTD, 1.5x vol — as of 22:46 UTC

Novo Nordisk shares trade at US$40.00, and the article examines whether that level is supported by earnings given new obesity and diabetes treatments and tougher competition.

The article says the 10.1x multiple screens as undervalued on its framework, and that Citi has flagged tougher GLP-1 competition from Eli Lilly, suggesting the market already prices in a fair amount of that pressure. Market: +2.2% today ($40.00), -20.8% YTD, 1.5x vol — as of 22:46 UTC